A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas



Status:Recruiting
Conditions:Cancer, Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/3/2019
Start Date:May 2016
End Date:January 2020
Contact:Hongwei Wang
Email:clinicaltrials@curis.com

Use our guide to learn which trials are right for you!

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients With Advanced Tumors and Lymphomas

CA-170 is a rationally designed and orally available, small molecule that directly targets
the Programmed death-ligands 1 and 2 (PD-L1/PD-L2), and V-domain Ig suppressor of T cell
activation (VISTA) immune checkpoints and results in activation of T cell proliferation and
cytokine production. This is a multi-center, open-label, Phase 1 trial of orally administered
CA-170 in adult patients with advanced solid tumors or lymphomas who have progressed or are
non-responsive to available therapies and for which no standard therapy exists.


Inclusion Criteria:

1. Males and females ≥ 18 years of age;

2. Life expectancy of at least 3 months;

3. ECOG PS ≤ 1;

4. Acceptable bone marrow and organ function at screening;

5. Ability to swallow and retain oral medications;

6. Negative serum pregnancy test in women of childbearing potential;

7. Measurable disease;

8. Tumor for which standard therapy, including approved anti-PD-1 or anti-PD-L1 therapy,
when applicable, does not exist or is no longer effective. For patients enrolling into
backfill of dose levels at or below the MTD/RP2D, patients with tumor types known to
have a high VISTA expression (such as metastatic malignant pleural mesothelioma of
epithelioid histology).

Exclusion Criteria:

1. Prior treatment anti-cancer therapy or use of any investigational agent within the
past 28 days or 5 half-lives, whichever is shorter;

2. Toxicity from prior chemotherapy that has not resolved to Grade ≤ 1;

3. Radiotherapy within the last 21 days;

4. Primary brain tumors or CNS metastases;

5. Major or minor surgery < 28 and <14 days from the start of treatment, respectively;

6. Active autoimmune disease or any medical condition requiring the use of systemic
immunosuppressive medications;

7. Endocrinopathies, unless on stable hormone replacement therapy;

8. Active infection requiring systemic therapy;

9. Receipt of live vaccines against infectious diseases within 28 days;

10. HIV positive or an AIDS-related illness;

11. Active/chronic HBV or HCV infection;

12. Uncontrolled CHF (NYHA Class 2-4), angina, MI, CVA, coronary/peripheral artery bypass
graft surgery, TIA, or PE in prior 3 months;

13. Cardiac dysrhythmias;

14. Gastrointestinal disease that interferes with receipt of oral drugs;

15. Concomitant malignancy;

16. Pregnant or lactating female;
We found this trial at
12
sites
Sarasota, Florida 34232
?
mi
from
Sarasota, FL
Click here to add this to my saved trials
9801 W. Kincey Ave
Huntersville, North Carolina 28078
704-947-6599
?
mi
from
Huntersville, NC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Denver, CO
Click here to add this to my saved trials
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
1515 Holcombe Blvd
Houston, Texas 77030
 713-792-2121
University of Texas M.D. Anderson Cancer Center The mission of The University of Texas MD...
?
mi
from
Houston, TX
Click here to add this to my saved trials
3322 West End Avenue
Nashville, Tennessee 37203
(615)329-SCRI (7274)
Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is a global strategic research organization...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
New Haven, Connecticut 06510
?
mi
from
New Haven, CT
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
200 Lothrop St
Pittsburgh, Pennsylvania 15213
University of Pittsburgh Medical Center UPMC is one of the leading nonprofit health systems in...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
?
mi
from
Seoul,
Click here to add this to my saved trials